WavoDyne Therapeutics is a newly founded pharmaceutical company based in Rochester, New York. The company is committed to developing novel therapeutics for patients suffering from cognition and memory impairment associated with neuroinflammation and neurodegeneration. The core technology of WavoDyne is a novel class of small molecule kinase inhibitors that are licensed from the University of Rochester Medical Center (URMC). WavoDyne's primary objective is to advance its leading drug candidate URMC-099 to Phase 2 clinical development for the treatment of Postoperative Cognitive Dysfunction (POCD) and HIV Associated Neurocognitive Disorders (HAND). More information about the company is available at www.wavodyne.com